ArticleTheranostics2026
Mitochondria-targeting organoselenium theranostic radioprotectors for simultaneous treatment and imaging of radiation-induced liver injury.
Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: Normal liver tissue is vulnerable towards ionizing radiation, which leads to radiation-induced liver injury (RILI) and remains a clinical challenge for treatment. Due to poor tissue targeting, mostly radioprotectors show limited radioprotective effect with a narrow therapeutic window. In this study, we report a series of selenium-substituted heptamethine cyanine derivatives (Se-Cys) as versatile radioprotectors for liver-preferential accumulation, simultaneous RILI imaging and treatment. Methods: A series of lipophilic cationic Se-Cys were developed with tunable properties for targeted delivery to liver mitochondria. We evaluated their deselenization kinetics in response to H Results: The targeting delivery and ROS-responsive selenium release, significantly enhance selenium levels in injured livers and mitochondria induced by ionizing radiation. Deselenization releases bioavailable selenium from Se-Cys, elevates selenoprotein expression and exerts endogenous radioprotective effect by activating the Keap1-Nrf2-HO-1 antioxidant axis. More interestingly, Se-Cys derivatives, especially Se-Cy4, possess a sensitive fluorescent enhancement in H Conclusions: Se-Cy4 serves as a novel theranostic agent for RILI, by providing ROS monitoring and robust radioprotection without detectable systemic toxicity. Our findings may also promise a potential of selenium-substituted heptamethine cyanines as next-generation radioprotectors for imaging-guided therapy of other radiation-induced diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.